Expert Cautions on Use of Antibiotics With Immunotherapy in Melanoma

Atezolizumab following vemurafenib and cobimetinib shows improved overall survival in BRAF V600–positive melanoma, but not statistically significant.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

Nivolumab, alone or with ipilimumab, significantly improved 10-year overall and melanoma-specific survival vs ipilimumab alone in advanced melanoma, according to final phase 3 CheckMate 067 trial data.

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

The subcutaneous version of the cancer treatment atezolizumab is approved in all adult intravenous indications, including in lung, liver, and skin cancers.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.